Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01603082 · ClinicalTrials.gov registry record · Phase 4
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
A Phase 4 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 343
- Enrollment target
NCT01603082 is a Phase 4 study that has completed, run by AstraZeneca. The registered enrollment target is 343 participants.
The verdict
NCT01603082, a Phase 4 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 343 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in ACS patients undergoing an Ad Hoc PCI
Interventions
- DRUG Clopidogrel
- DRUG Ticagrelor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 343 participants |
| Start Date | 2012-07 |
| Est. Completion | 2014-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01603082
The ClinicalTrials.gov registry entry for NCT01603082 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 343 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Clopidogrel is the first listed.
NCT01603082 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01603082 about?
NCT01603082 is a clinical study titled "Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients". The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in ACS patients undergoing an Ad Hoc PCI
What is the current status of trial NCT01603082?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 343 participants. The study started on 2012-07. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01603082?
The interventions under investigation include: Clopidogrel (DRUG), Ticagrelor (DRUG).
Who is sponsoring clinical trial NCT01603082?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.